Marketing Aspects of Company-Sponsored Postmarketing Surveillance Studies

Drug Safety

Volumn 8, Issue 1, 1993, Pages 1-8

  Stephens, Myles D B ^a  

^a NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NEW DRUG;

CLINICAL STUDY; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; DRUG SAFETY; DRUG SCREENING; DRUG SURVEILLANCE PROGRAM; HUMAN; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; REVIEW;

DRUG INDUSTRY; HUMAN; MARKETING OF HEALTH SERVICES; PRODUCT SURVEILLANCE, POSTMARKETING;

EID: 0027397608     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/00002018-199308010-00001     Document Type: Article

References (22)

1. Position paper on the use of purported postmarketing drug surveillance studies for promotional purposes
2. A report of the Post-marketing Surveillance Working Party
3. WHO cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up
4. Postmarketing surveillance: lessons learned
5. Postmarketing surveillance for drug safety
6. Worldwide regulations for manufacturers on clinical safety surveillance of drugs
7. PEM 2000
8. Guidelines on postmarketing surveillance
9. Channeling bias in the interpretation of drug effects
10. Postmarketing surveillance of adverse reactions to drugs
11. Postapproval research as a condition of approval: an update, 1985–1986
12. Discovery of adverse drug reactions: a comparison of selected phase IV studies with spontaneous reporting methods
13. Postmarketing drug surveillance
14. Pharmaceutical company viewpoint
15. Review of company postmarketing surveillance studies
16. Epidemiology of adverse reactions to non-steroidal anti-inflammatory drugs